NervGen Pharma Appoints Dr. Michael Abrams to Board of Directors
Vancouver, Canada. September 25, 2018 – NervGen Pharma Corp. (“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Dr. Michael J. Abrams, PhD, to the Company’s Board of Directors. Dr. Abrams brings to NervGen extensive expertise and successes gained during his over thirty-year […]
NervGen Pharma Announces Granting of US Patent for Breakthrough Nerve Regeneration Technology
Vancouver, B.C. August 10, 2018 NervGen Pharma Corp. (“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of a patent central to the development and commercialization of protein tyrosine phosphatase sigma (PTPs) targeted therapies for spinal cord injury […]
NervGen Pharma Licenses Breakthrough Nerve Regeneration Technology from Case Western Reserve University
July 17, 2018—NervGen Pharma Corp. (“NervGen”), in Vancouver, and Case Western Reserve University (“Case Western Reserve”) in Cleveland have entered into an exclusive worldwide licensing agreement to research, develop and commercialize a patented technology with potential to bring new therapies for spinal cord injury and other conditions associated with nerve damage. The technology was developed […]
NervGen Pharma Appoints Dr. Ernest Wong as President & CEO
Experienced Biotechnology Executive to Lead Innovative Regenerative Medicine Company Dedicated to Creating Solutions for the Treatment of Nerve Damage Vancouver, Canada. June 21, 2018 – NervGen Pharma Corp. (“NervGen”), a private regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of spinal cord injury and nerve damage, today announced the appointment […]
